Nonerosive reflux disease - Current concepts and dilemmas

American Journal of Gastroenterology

Volumn 96, Issue 2, 2001, Pages 303-314

  Fass, Ronnie ^a   Fennerty, M Brian ^b   Vakil, Nimish ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

ACID SECRETION; CHRONIC DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ENDOSCOPY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH ECONOMICS; HEARTBURN; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; QUALITY OF LIFE; REFLUX ESOPHAGITIS; REVIEW; STOMACH PH;

COSTS AND COST ANALYSIS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; QUALITY OF LIFE; UNITED STATES;

EID: 0035120362     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)02304-2     Document Type: Review

References (99)

1. Prevalence and clinical spectrum of gastroesophageal reflux: A population based study in Olmstead County, Minnesota
2. Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment
3. Endoscopic assessment of oesophagitis: Clinical and functional correlates and further validation of the Los Angeles classification
4. Healing and relapse of severe peptic esohagitis after treatment with omeprazole
5. Methodologic aspects of evaluation of quality of life in upper gastrointestinal disease
6. Functional esophageal disorders
7. The clinical and economic value of a short course of omeprazole in patients with non-cardiac chest pain
8. Omeprazole as a diagnostic tool in gastroesophageal reflux disease
9. Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux the "sensitive oesophagus."
10. Symptoms in gastro-oesophageal reflux disease
11. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease
12. Barrett's esophagus. A prevalent, occult complication of gastroesophageal reflux disease
13. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease
14. Heartburn without oesophagitis: Efficacy of omeprazole therapy and features determining therapeutic response
15. Gastroesophageal reflux disease in primary care in Europe: Clinical presentation and endoscopic findings
16. Heartburn requiring frequent antacid use may indicate significant illness
17. Natural history of gastro-oesophageal reflux disease without oesophagitis
18. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux
19. Sensory afferents from gastrointestinal tract
20. Vegetative innervation of the esophagus. III. Intraepithelial endings
21. Vegetative innervation of the esophagus. II. Intraganglionic laminar endings
22. Gastrointestinal afferent fibers and sensation
23. Visceral nerve stimulation and pain modulation
24. Mapping of cerebral response to vagal and esophageal stimulation using positron emission tomography (PET) and topography EEG in humans
25. Basic and clinical aspects of visceral hyperalgesia
26. The effect of low external pH on properties of the paracellular pathway and junctional structure in frog skin
27. Electron microscopic changes in human oesophageal epithelium in oesophagitis
28. Dilated intercellular spaces: A morphological feature of acid reflux-damaged human esophageal epithelium
29. Pathophysiology of gastroesophageal reflux disease
30. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease
31. Evaluation of the omeprazole test in patients with typical symptoms of gastroesophageal reflux disease (GERD)
32. Ambulatory 24-hour esophageal pH monitoring: Reproducibility and variability of pH parameters
33. The symptom index: A clinically important parameter of ambulatory 24-hour esophageal pH monitoring
34. The symptom index: Differential usefulness in suspected acid-related complaints of heartburn and chest pain
35. Symptom index as a marker of gastro-oesophageal reflux disease
36. Sensitivity of the esophageal mucosa to pH in gastroesophageal reflux disease
37. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans
38. Chemosensitivity to acid in patients with persistent heartburn on standard doses of proton pump inhibitor and normal 24-h esophageal pH monitoring
39. Segmental acid sensitivity of the esophagus in patients with endoscopy-negative GERD
40. The acid perfusion test in gastroesophageal reflux disease
41. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: Evidence for a spectrum of visceral sensitivity in GORD
42. Sustained esophageal contraction: A motor correlate of heartburn symptom
43. Acid gastroesophageal reflux and symptom occurrence: Analysis of some factors influencing their association
44. Intraduodenal fat alters perceptual and autonomic responses to acid perfusion of the esophagus in GERD patients
45. Does acute emotional stress influence frequency or duration of gastroesophageal reflux in human subjects?
46. The relationship between stress and symptoms of gastroesophageal reflux: The influence of physiological factors
47. Relaxation training reduces symptom reports and acid exposure in patients with gastroesophageal reflux disease
48. Effect of acute stress on oesophageal motility in patients with gastro-oesophageal reflux disease
49. Psychophysiological interactions in esophageal diseases
50. Psychological distress in patients with gastroesophageal reflux disease
51. Acid perception in gastro-oesophageal reflux disease is dependent on psychological factors
52. Esophageal peristaltic dysfunction in peptic esophagitis
53. pH monitoring versus other tests for gastroesophageal reflux disease: Is this the gold standard?
54. Technique, indications, and clinical use of 24 hour esophageal pH monitoring
55. Is long-term esophageal pH monitoring of clinical value?
56. Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease
57. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease
58. Empiric therapy for gastroesophageal reflux disease
59. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus
60. Inflammatory disorders of the esophagus, reflux and nonreflux types
61. Microscopic appearance of the esophageal mucosa in a consecutive series of patients submitted to upper endoscopy. Correlation with gastroesophageal reflux symptoms and macroscopic findings
62. Diagnostic value of histology in non-erosive gastro-oesophageal reflux disease
63. American Gastrointestinal Association medical position statement: Guidelines on the use of esophageal pH recording
64. Persistent symptoms of heartburn in patients on standard doses of proton pump inhibitors (PPI) are not due to acid reflux in most patients
65. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis
66. The effects of ranitidine on symptom relief and quality of life of patients with gastro-esophageal reflux disease
67. Quality of life and cost of therapy in reflux disease
68. Clinical effectiveness and quality of life with ranitidine vs. placebo in gastroesophageal reflux disease patients: Clinical experience network study
69. The impact of gastroesophageal reflux disease on health related quality of life
70. Gastro-oesophageal reflux disease in primary care: An international study of different treatment strategies with omeprazole
71. Quality of life in patients with heartburn but without esophagitis: Effects of treatment with omeprazole
72. H2-receptor antagonists in the treatment of complicated gastroesophageal reflux disease. For whom the bell tolls
73. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose ranging study
74. High versus standard-dose ranitidine for control of heartburn in poorly-responsive gastroesophageal reflux disease: A prospective controlled trial
75. The effect of cisapride in maintaining symptomatic remission in patients with gastroesophageal reflux disease
76. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
77. Reflux symptom relief with omeprazole in patients without unequivocal esophagitis
78. Omeprazole 10mg once daily, omeprazole 20mg once daily or ranitidine 150mg twice daily, evaluated as initial therapy for the relief of symptoms of gastroesophageal reflux in general practice
79. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease
80. Treating the symptoms of gastroesophageal reflux disease: A double-blind comparison of omeprazole and cisapride
81. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis
82. Costs of acid reflux disorders to a health maintenance organization
83. Why endoscopy is performed: Results of a national consortium
84. The cost-effectiveness of the omeprazole test in patients with non-cardiac chest pain
85. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease
86. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma
87. Empirical therapy versus diagnostic tests in gastroesophageal reflux disease
88. Management of symptoms of gastroesophageal reflux disease: Does endoscopy influence medical management?
89. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms
90. What happens to patients with non-ulcer dyspepsia after endoscopy?
91. Does endoscopy have a positive impact on quality of life in dyspepsia?
92. Responses of consecutive patients to reassurance after gastroscopy: Results of self administered questionnaire survey
93. Economic analysis of step-wise treatment of gastro-esophageal reflux disease
94. Heartburn. Is "step-up/step down" out of step, evidence from a large community-based trial
95. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary clinics in West Virginia
96. Symptomatic gastro-esophageal reflux disease: Double blind controlled study of intermittent treatment with omeprazole or ranitidine
97. Cost-effectiveness of omeprazole and ranitidine in intermittent treatment of symptomatic GERD
98. On demand therapy with omeprazole for the long-term management of patients with heartburn without esophagitis - A placebo-controlled randomized trial